Breaking News

Financial Report: Elan

July 24, 2013

Completes Tysabri transaction

Elan
 
2Q Revenues:
$56.3 million ($0.2 million 2Q12)

2Q Earnings: $2.3 billion (loss of $28.5 million 2Q12)

YTD Revenues: $56.5 million (n/a)

YTD Earnings: $2.4 billion (loss of $60.3 million YTD12)

Comments: Results included $2.5 billion income from the transfer of Tysabri to partner Biogen. Under the Tysabri transaction, Elan received an upfront payment of $3.3 billion and will continue to receive royalties on Tysabri in-market sales. Earnings in the quarter includes a net loss from continuing operations of $251.8 million ($90.0 million 2Q12) and net income from discontinued operations of $2.5 billion. YTD earnings includes a net loss from continuing operations of $324.6 million ($164.7 million YTD12), and net income from discontinued operations of $2.7 billion ($104.4 million in YTD12) related to the Tysabri, Prothena and EDT businesses. According to a board announcement in June, Elan is in the process of exploring the sale of the company.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision